Supplementary Tables 1 - 3 from VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy

Erick Riquelme,Milind Suraokar,Carmen Behrens,Heather Y. Lin,Luc Girard,Monique B. Nilsson,George Simon,Jing Wang,Kevin R. Coombes,J. Jack Lee,Waun Ki Hong,John Heymach,John D. Minna,Ignacio I. Wistuba
DOI: https://doi.org/10.1158/1078-0432.22445921
2023-01-01
Abstract:PDF file - 136KB, Supplementary Table 1. Sumary of the clinicopathological characteristics of the patients with lung adecarcinomas examined for EZH2 and miR-101 expressions. Supplementary Table 2. Association between markers' expression and lung adenocarcinoma patient's clinical and pathological characteristics. Supplementary Table 3. Summary of Multivariate Analysis of Outcome in Lung Adenocarcinoma Patients by Adjuvant Chemoterapy and EZH2, miR-101 and Combination of EZH2/miR-101 Expression.
What problem does this paper attempt to address?